Merck & Co. reported positive results from the Phase III KEYNOTE-689 trial of KEYTRUDA for head and neck cancer treatment. The trial met its primary endpoint of event-free survival, with significant improvements in key secondary endpoints like major pathological response. The safety profile was consistent with previous studies.
Read MoreDid you find this insightful?
Bad
Just Okay
Amazing